



CANNABIDIOL (CBD)

PURE CBD (0% THC LEVEL)

FDF Worldwide market size and growth




The pharmaceutical industry has seen a stupendous rise in research, technologies and drugs based on cannabinoids.⁽¹⁾

2021
Global Market Growth
22,2%
Value USD\$
22.2 billion



2031
Projected
Value USD\$
154.2 billion

CBD THERAPEUTICAL EFFECTS



The cannabis plant contains more than 500 components, but the most known and researched are cannabidiol (CBD), $\Delta 9$ -tetrahydrocannabinol ($\Delta 9$ -THC) and cannabigerol (CBG) from the cannabinoid group.^(7,10)

CBD does not act on CB receptors directly, but as a negative allosteric modulator of the CB receptors.^(11,12)

Potential therapeutic effects of CBD⁽¹³⁾

- Anxiolytic
- Antipsychotic
- Antidepressant
- Antiepileptic
- Antispastic
- Anti-inflammatory




50 million

people suffer
from some type
of epilepsy⁽¹⁴⁾

POTENTIAL USES OF CANNABIDIOL

 Cannabidiol can be used in cosmetic products⁽¹⁵⁾



Cannabidiol effects:

- Antioxidant^(16, 17)
- Anti-inflammatory^(16, 17)
- Photo-protective^(17, 18)

Potential topical applications:

- Acne⁽¹⁹⁾
- Seborrhea^(20, 21)
- Atopic Dermatitis^(20, 22)
- Psoriasis⁽²⁰⁻²²⁾



Our manufacturer is certified by the FDA & DEA

Batch size 50 KG
Annual Capacity 7200 KG

References

- (1) PharmaCompass. Biosynthesis, tech advancements trigger high growth in medical cannabinoids. Available at https://www.pharmacompas.com/radio-compass-blog/biosynthesis-tech-advancements-trigger-high-growth-in-medical-cannabinoids?mc_cid=05137b076d&mc_eid=782daef9bb (Accessed on August 1st, 2022). 2022. (2) Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. *Alcohol Alcohol*. 2005;40(1):2-14. (3) Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. *Trends Neurosci*. 1998;21(12):521-8. (4) Bukke VN, Archana M, Villani R, Servidio G, Cassano T. Pharmacological and Toxicological Effects of Phyto cannabinoids and Recreational Synthetic Cannabinoids: Increasing Risk of Public Health. *Pharmaceutics (Basel)*. 2021;14(10). (5) EMCDDA. European Monitoring Centre for Drugs and Drug Addiction - Medical use of cannabis and cannabinoids: questions and answer for policymaking. Available at https://www.emcdda.europa.eu/publications/rapid-communications/medical-use-of-cannabis-and-cannabinoids-questions-and-answers-for-policymaking_en. 2018. (6) Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet*. 2003;42(4):327-60. (7) Pertwee R. Handbook of Cannabis. Available at <https://academic.oup.com/book/27329>. 2014. (8) Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev*. 2002;54(2):161-202. (9) Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. *Int J Mol Sci*. 2018;19(3). (10) Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laenza C. Cannabinoids: Therapeutic Use in Clinical Practice. *Int J Mol Sci*. 2022;23(6). (11) Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br J Pharmacol*. 2015;172(20):4790-805. (12) Martinez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, et al. Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors. *Front Pharmacol*. 2017;8:744. (13) Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol Sci*. 2009;30(10):515-27. (14) WHO. Epilepsy. Available at <https://www.who.int/news-room/fact-sheets/detail/epilepsy>. Accessed on August 1st, 2022. 2022. (15) INCOA. The International Natural and Organic Cosmetics Association (INCOA) - How are hemp and other Cannabis sativa L. extracts used in cosmetics? Available at <https://www.natrc.org/how-are-hemp-and-other-cannabis-sativa-l-extracts-used-in-cosmetics/>. 2022. (16) Atalay S, Jarocka-Karpowicz I, Skrzylewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. *Antioxidants (Basel)*. 2019;9(1). (17) Jastrząb A, Jarocka-Karpowicz I, Markowska A, Wroński A, Gegotek A, Skrzylewska E. Antioxidant and Anti-Inflammatory Effect of Cannabidiol ContrIBUTES to the Decreased Lipid Peroxidation of Keratinocytes of Rat Skin Exposed to UV Radiation. *Oxidative Medicine and Cellular Longevity*. 2021;2021:6647222. (18) Gegotek A, Atalay S, Rogowska-Wrzesińska A, Skrzylewska E. The Effect of Cannabidiol on UV-Induced Changes in Intracellular Signaling of 3D-Cultured Skin Keratinocytes. *Int J Mol Sci*. 2021;22(3). (19) Peyravian N, Deo S, Daunert S, Jimenez JJ. The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne. *J Inflamm Res*. 2022;15:2795-801. (20) Sivesind TE, Maghfour J, Rietcheck H, Kamel K, Malik AS, Dellavalle RP. Cannabinoids for the Treatment of Dermatologic Conditions. *JID Innov*. 2022;2(2):100095. (21) Vincenzi C, Tosti A. Efficacy and Tolerability of a Shampoo Containing Broad-Spectrum Cannabidiol in the Treatment of Scalp Inflammation in Patients with Mild to Moderate Scalp Psoriasis or Seborrheic Dermatitis. *Skin Appendage Disord*. 2020;6(6):355-61. (22) Palmieri B, Laurino C, Vadala M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. *Clin Ter*. 2019;170(2):e93-e9. 23. Fiani B, Sarhadi KJ, Soula M, Zafar A, Quadri SA. Current application of cannabidiol (CBD) in the management and treatment of neurological disorders. *Neurol Sci*. 2020;41(11):3085-98. 24. Silvestro S, Mammina S, Cavalli E, Bramanti P, Mazzon E. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Safety in Clinical Trials. *Molecules*. 2019;24(8).



Want to know more about CANNABIDIOL?
CONTACT Jovani Valdovinos
lvaldovinos@helmag.com